CTOs on the Move

New York Genome Center

www.nygenome.org

 
The New York Genome Center (NYGC) is at the forefront of transforming biomedical research and clinical care with the mission of saving lives. As a consortium of renowned academic, medical and industry leaders across the globe, NYGC focuses on translating genomic research into clinical solutions for serious disease. Our member organizations are united in this unprecedented collaboration of technology, science, and medicine. We implement advanced genomic research, and integrate our findings with world-class technologies and physician-scientists in order to help solve diseases. We harness the diversity of New York`s institutions and people to drive scientific discoveries that will vastly improve clinical ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.nygenome.org
  • 101 Avenue of the Americas
    New York, NY USA 10013
  • Phone: 646.977.7000

Executives

Name Title Contact Details

Funding

New York Genome Center raised $125M on 05/23/2019

Similar Companies

Cosmetic Industries

Cosmetic Industries, Inc is a Fontana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CareSite Pharmacy

CareSite Pharmacy is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Claims Strategies

Innovative Claims Strategies is a Iselin, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.

Encision Inc.

Encision Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Boulder, CO. To find more information about Encision Inc., please visit www.encision.com